Two Biotechnology Names Are Hot: Bioverativ (BIVV), Novavax (NVAX) – The Independent Republic

Bioverativ Inc. (BIVV) ended last trading session with a change of 3.76 percent. It trades at an average volume of 13.38M shares versus 3.28M shares recorded at the end of last trading session. The share price of $44.44 is at a distance of 4.81 percent from its 52-week low and down -4.22 percent versus its peak. The company has a market cap of $4.86B and currently has 109.41M shares outstanding. The share price is currently 0.85 percent versus its SMA20, 0.85 percent versus its SMA50, and 0.85 percent versus its SMA200. The stock has a weekly performance of 0 percent and is -1.2 percent year-to-date as of the recent close.

Bioverativ Inc. (BIVV) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Novavax, Inc. (NVAX) recently recorded -1.5 percent change and currently at $1.31 is 12.93 percent away from its 52-week low and down -84.57 percent versus its peak. It has a past 5-day performance of 0 percent and trades at an average volume of 7.16M shares. The stock has a 1-month performance of -4.38 percent and is 3.97 percent year-to-date as of the recent close. There were about 271.06M shares outstanding which made its market cap $355.09M. The share price is currently -3.43 percent versus its SMA20, -2.25 percent versus its SMA50, and -68.14 percent versus its SMA200.

On Jan. 19, 2017 Novavax, Inc. (NVAX) announced the initiation of a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults (60 years of age and older).

The objective of the trial is to assess safety and immunogenicity to one and two dose regimens of the RSV F Vaccine, with and without aluminum phosphate or Novavax` proprietary Matrix-M(TM) adjuvant, in older adults. The trial is a randomized, observer-blinded, placebo-controlled trial designed to enroll up to 300 older adults in the Southern Hemisphere. Participants are being enrolled and vaccinated outside of the RSV season to best assess immunogenicity. Top-line results are expected in the third quarter of 2017.

See the original post here:
Two Biotechnology Names Are Hot: Bioverativ (BIVV), Novavax (NVAX) - The Independent Republic